DK3444268T3 - Staphylococcus aureus-leukocidiner, terapeutiske sammensætninger og anvendelser deraf - Google Patents

Staphylococcus aureus-leukocidiner, terapeutiske sammensætninger og anvendelser deraf Download PDF

Info

Publication number
DK3444268T3
DK3444268T3 DK18196549.2T DK18196549T DK3444268T3 DK 3444268 T3 DK3444268 T3 DK 3444268T3 DK 18196549 T DK18196549 T DK 18196549T DK 3444268 T3 DK3444268 T3 DK 3444268T3
Authority
DK
Denmark
Prior art keywords
leucocidins
applications
staphylococcus aureus
therapeutic compositions
therapeutic
Prior art date
Application number
DK18196549.2T
Other languages
English (en)
Inventor
Victor J Torres
Ashley L Dumont
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of DK3444268T3 publication Critical patent/DK3444268T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
DK18196549.2T 2010-05-05 2011-05-05 Staphylococcus aureus-leukocidiner, terapeutiske sammensætninger og anvendelser deraf DK3444268T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33155010P 2010-05-05 2010-05-05
EP16187485.4A EP3121191B1 (en) 2010-05-05 2011-05-05 Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof

Publications (1)

Publication Number Publication Date
DK3444268T3 true DK3444268T3 (da) 2022-01-31

Family

ID=44902083

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18196549.2T DK3444268T3 (da) 2010-05-05 2011-05-05 Staphylococcus aureus-leukocidiner, terapeutiske sammensætninger og anvendelser deraf

Country Status (21)

Country Link
US (5) US8431687B2 (da)
EP (4) EP3444268B1 (da)
JP (4) JP6031029B2 (da)
KR (3) KR20190133290A (da)
CN (2) CN103025352B (da)
AU (5) AU2011247989C1 (da)
BR (1) BR112012029521A2 (da)
CA (2) CA2798355C (da)
DK (1) DK3444268T3 (da)
ES (2) ES2904314T3 (da)
HR (1) HRP20220068T1 (da)
HU (1) HUE058787T2 (da)
IL (2) IL222874B (da)
LT (1) LT3444268T (da)
MX (4) MX364642B (da)
MY (1) MY165618A (da)
PL (1) PL3444268T3 (da)
RU (2) RU2644237C2 (da)
SI (1) SI3444268T1 (da)
WO (1) WO2011140337A2 (da)
ZA (4) ZA201208455B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX364642B (es) * 2010-05-05 2019-05-03 Univ New York Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.
US9091689B2 (en) * 2011-06-19 2015-07-28 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions
RU2014145830A (ru) 2012-04-17 2016-06-10 Арсанис Байосайенсиз Гмбх Перекрестно-реактивные антитела против staphylococcus aureus
US9657103B2 (en) 2012-05-02 2017-05-23 New York University Methods of treating and preventing Staphylococcus aureus infections and associated conditions
KR101826538B1 (ko) * 2012-05-30 2018-02-07 현대자동차 주식회사 차량용 글래스 몰딩 부착 장치 및 그 방법
JP6560195B2 (ja) * 2013-05-21 2019-08-14 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 黄色ブドウ球菌のＬｕｋＧＨ（ＬｕｋＡＢ）毒素を中和する、非常に強力な抗体の生成
DK3441474T3 (da) 2013-06-18 2020-08-17 Univ New York Farmaceutiske sammensætninger indeholdende et muteret leukocidin e
CA2925071A1 (en) * 2013-10-17 2015-04-23 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
KR20160097294A (ko) 2013-12-09 2016-08-17 뉴욕 유니버시티 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
JP2017505758A (ja) * 2013-12-19 2017-02-23 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 黄色ブドウ球菌のｌｕｋｇｈ（ｌｕｋａｂ）毒素に対する抗体及び抗体配列
EP3302532A4 (en) 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS RELATED TO ANTISTAPHYLOCOCCAL BIOLOGICAL AGENTS
WO2018165089A1 (en) * 2017-03-06 2018-09-13 Vanderbilt University Human monoclonal antibodies to staphylococcus aureus lukab toxin
US11421021B2 (en) * 2017-06-13 2022-08-23 Integrated Biotherapeutic Vaccines, Inc. Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
KR102061735B1 (ko) * 2018-06-08 2020-01-02 대한민국(농림축산식품부 농림축산검역본부장) 황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물
US11155606B2 (en) 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
TW202035443A (zh) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌抗體的組合
EP3864040A1 (en) 2018-10-09 2021-08-18 Medimmune, LLC Antibodies directed against staphylococcus aureus leukotoxins
MX2022004061A (es) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Peptidos de estafilococo y metodos de uso.
KR20230091911A (ko) * 2020-09-28 2023-06-23 얀센 파마슈티칼즈, 인코포레이티드 변이체 스태필로코쿠스 아우레우스 LukA 및 LukB 폴리펩티드 및 백신 조성물
KR20230165808A (ko) * 2021-04-02 2023-12-05 얀센 파마슈티칼즈, 인코포레이티드 스태필로코쿠스 아우레우스 백신 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US300A (en) 1837-07-29 Machine foe spinning woolen roving
US400A (en) 1837-09-25 Mode of causing puppet valves to work lights
RU2122862C1 (ru) * 1995-12-08 1998-12-10 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US20020061569A1 (en) 2000-03-21 2002-05-23 Robert Haselbeck Identification of essential genes in prokaryotes
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2003303301B2 (en) 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
NZ565069A (en) * 2005-06-13 2011-08-26 Glaxosmithkline Biolog Sa Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
CN100485038C (zh) * 2005-09-13 2009-05-06 四川大学华西医院 小型化抗耐药金黄色葡萄球菌多肽及其应用与制备方法
WO2007100580A2 (en) * 2006-02-22 2007-09-07 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
KR20090019007A (ko) * 2006-06-12 2009-02-24 나비 바이오파마슈티컬즈 스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도
CN101535811B (zh) * 2006-10-18 2016-05-04 生物梅里埃公司 用于体外诊断产pvl金黄色葡萄球菌的方法
GB0624340D0 (en) * 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
CN101951948B (zh) * 2007-08-31 2015-12-09 芝加哥大学 与针对葡萄球菌性肺部疾病和病症进行免疫相关的方法和组合物
US9593340B2 (en) 2007-10-15 2017-03-14 Admedus Vaccines Pty Ltd. Expression system for modulating an immune response
CN101182350A (zh) * 2007-11-02 2008-05-21 山东省农业科学院奶牛研究中心 金黄色葡萄球菌α-溶血素及其编码序列
WO2009111177A2 (en) * 2008-03-05 2009-09-11 Mount Sinai School Of Medicine Of New York University Compositions and methods comprising genetically enhanced obligate and facultative anaerobic bacteria for oncopathic cancer therapy
WO2009140236A2 (en) 2008-05-12 2009-11-19 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
RU2579897C2 (ru) 2008-09-26 2016-04-10 Онкомед Фармасьютикалс, Инк. Агенты, связывающие рецептор "frizzled", и их применение
US8679505B2 (en) * 2009-04-14 2014-03-25 Novartis Ag Compositions for immunising against Staphylococcus aureus
MX364642B (es) * 2010-05-05 2019-05-03 Univ New York Leucocidinas de staphylococcus aureus, composiciones terapeuticas y usos de las mismas.

Also Published As

Publication number Publication date
CN103025352A (zh) 2013-04-03
CN103025352B (zh) 2017-07-11
AU2016262661A1 (en) 2016-12-08
ZA201603107B (en) 2018-09-26
AU2021236457B2 (en) 2024-05-02
IL222874A0 (en) 2012-12-31
US20130095115A1 (en) 2013-04-18
AU2011247989C1 (en) 2015-05-14
MX2021003906A (es) 2021-09-30
AU2011247989B2 (en) 2014-11-27
US10316067B2 (en) 2019-06-11
WO2011140337A3 (en) 2012-03-15
CA2798355C (en) 2020-09-15
US20230295248A1 (en) 2023-09-21
JP2017048206A (ja) 2017-03-09
ES2605476T3 (es) 2017-03-14
CA2798355A1 (en) 2011-11-10
LT3444268T (lt) 2022-04-11
CA3088918A1 (en) 2011-11-10
IL222874B (en) 2020-05-31
EP3444268A1 (en) 2019-02-20
ZA201208455B (en) 2016-07-27
US20190330284A1 (en) 2019-10-31
EP4015523A1 (en) 2022-06-22
AU2015200901B2 (en) 2016-12-15
AU2019222824A1 (en) 2019-09-19
KR101933226B1 (ko) 2018-12-28
KR20180137612A (ko) 2018-12-27
MX2012012859A (es) 2013-03-20
EP2566519A2 (en) 2013-03-13
IL274109A (en) 2020-06-30
KR20130060230A (ko) 2013-06-07
US20110274693A1 (en) 2011-11-10
AU2015200901A1 (en) 2015-03-12
HUE058787T2 (hu) 2022-09-28
MX364642B (es) 2019-05-03
JP6253742B2 (ja) 2017-12-27
JP6031029B2 (ja) 2016-11-24
JP2020055835A (ja) 2020-04-09
KR102050078B1 (ko) 2019-11-28
CN107286224A (zh) 2017-10-24
EP2566519A4 (en) 2014-01-15
RU2677140C1 (ru) 2019-01-15
JP7001661B2 (ja) 2022-02-21
EP2566519B1 (en) 2016-09-07
RU2018146933A (ru) 2020-06-29
AU2021236457A1 (en) 2021-10-14
MY165618A (en) 2018-04-18
KR20190133290A (ko) 2019-12-02
SI3444268T1 (sl) 2022-05-31
US9783582B2 (en) 2017-10-10
EP3121191A1 (en) 2017-01-25
EP3444268B1 (en) 2021-12-15
PL3444268T3 (pl) 2022-04-19
BR112012029521A2 (pt) 2018-03-06
EP3121191B1 (en) 2018-09-26
US8431687B2 (en) 2013-04-30
US20180099998A1 (en) 2018-04-12
AU2011247989A1 (en) 2012-12-06
HRP20220068T1 (hr) 2022-04-15
AU2016262661B2 (en) 2019-07-25
ES2904314T3 (es) 2022-04-04
JP2013531620A (ja) 2013-08-08
RU2644237C2 (ru) 2018-02-08
JP6678634B2 (ja) 2020-04-08
WO2011140337A2 (en) 2011-11-10
MX2019005156A (es) 2019-08-05
US11584782B2 (en) 2023-02-21
ZA201802995B (en) 2020-12-23
ZA202002470B (en) 2022-12-21
JP2018076324A (ja) 2018-05-17
RU2012152086A (ru) 2014-06-10

Similar Documents

Publication Publication Date Title
ZA202002470B (en) Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
DK2925293T3 (da) Topiske tetracyclinformuleringer, fremstilling og anvendelser deraf
BR112013011844A2 (pt) composições pesticidas agrícolas
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
BR112013006293A2 (pt) arilpirrolidinas pesticidas
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
BR112015002738A2 (pt) composto , e , composição farmacêutica
DK2585437T3 (da) Thioacetatforbindelser, sammensætninger og fremgangsmåder til anvendelse heraf
DK3175711T3 (da) Parasitiske sammensætninger indeholdende multiple aktivstoffer, fremgangsmåder og anvendelser deraf
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
BR112012024023A2 (pt) Misturas pesticidas
BR112013010782A2 (pt) combinações pesticidas
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
FI20115816L (fi) Antimikrobinen ionomeerikoostumus sekä sen käyttösovellukset
BR112012013182A2 (pt) composições tópicas germicidas
DK2547361T3 (da) Bakterielle vaccinekomponenter fra staphylococcus aureus og anvendelser deraf
DK2917212T3 (da) Antimikrobielle midler
BR112014028443A2 (pt) composição estéril.
BR112013013165A2 (pt) composição herbicida compreendendo flazassulfuron e nicossulfuron
BR112013009512A2 (pt) composição herbicida
DK2598175T3 (da) Radiofarmaceutiske sammensætninger
DK2563375T3 (da) Farmaceutiske sammensætninger med phosphonium-antimikrobielle midler
DK3241569T3 (da) Antimikrobiel sammensætning
DK2558132T3 (da) Antimikrobiel gel
FI20105517A0 (fi) Antimikrobinen koostumus